Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality
- 12 April 2021
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (8) , 2005-2012
Abstract
Despite low nonrelapse mortality (NRM) at day 100 after allogeneic hematopoietic cell transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively analyzed 199 patients who were treated on a phase II clinical trial assessing safety and efficacy of myeloablative fractionated busulfan and fludarabine conditioning regimen for hematologic malignancies. The goal of the study was to identify factors associated with NRM occurring between days 101 and 365 post-HCT and generate a hypothesis for future studies to reduce the risk of NRM at 1 year. We found that a vast majority (83%) of patients who experienced NRM between days 101 and 365 had prior grade II-IV acute graft-versus-host disease (GVHD), which was the leading cause of death either by itself (33.3%) or complicated by infections (37.5%). In multivariate analysis, grade II-IV acute GVHD (hazard ratio (HR) 2.9, 95% confidence interval (CI) 1.3–6.6, p = 0.01) was the only significant predictor of NRM between days 101 and 365. Measures to reduce the risk of acute GVHD could lower the risk of NRM at 1 year and improve overall survival.Keywords
This publication has 27 references indexed in Scilit:
- Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine ConditioningJournal of Clinical Oncology, 2014
- Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated DonorsJournal of Clinical Oncology, 2013
- Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspectiveBone Marrow Transplantation, 2009
- Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trialThe Lancet Oncology, 2009
- A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion TrialTransplantation and Cellular Therapy, 2007
- Prediction of Nonrelapse Mortality for Patients Surviving 100 Days After Allogeneic Hematopoietic Stem Cell TransplantationTransplantation Proceedings, 2007
- Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor TransplantationTransplantation and Cellular Therapy, 2006
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Chronic graft-versus-host syndrome in manThe American Journal of Medicine, 1980
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974